CIRSE

IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights

Retrieved on: 
Wednesday, November 15, 2023
Lung, Woman, CIRSE, Freezing, Patient, Participation, Research, Kidney, Marketing, Neoplasm, Conference, Congress, System, ICE3, Hamas, Webcast, Safety, Food, Luminate (company), European Society of Radiology, Conference call, ANVISA, Health, Breast, Cryoablation, Breast cancer, Kidney cancer, Nine Months, Classification, Brazilian Health Regulatory Agency, Prostate, Health Canada, De novo, Circulatory system, Liver, Novomer, Episcopal conference, FDA, Cancer Diagnostic Probe, Medical device, Pharmaceutical industry, Nursing, Medical imaging, Birth control, Cryptocurrency, Broadcasting, Luminal

Gross profit was $0.73 million for the nine months ended September 30, 2023, compared to $0.98 million for the nine months ended September 30, 2022.

Key Points: 
  • Gross profit was $0.73 million for the nine months ended September 30, 2023, compared to $0.98 million for the nine months ended September 30, 2022.
  • Gross margin was 37% for the nine months ended September 30, 2023, compared to 46% for the nine months ended September 30, 2022.
  • Research and development expenses for the nine months ended September 30, 2023, were $6.39 million compared to $6.89 million for the nine months ended September 30, 2022.
  • Total operating expenses for the nine months ended September 30, 2023, were $12.89 million, compared to $13.79 million for the nine months ended September 30, 2022.

Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023

Retrieved on: 
Friday, September 8, 2023
Cardiovascular and Interventional Radiological Society of Europe, Miniature, ZEUS robotic surgical system, Clinical trial, Coronavirus Scientific Advisory Board, CIRSE, Doctor of Philosophy, Aix-Marseille University, MDR, Professor, Circulatory system, FIH, FDA, Microbotics

BRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023.

Key Points: 
  • BRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023.
  • The abstract is to be presented by Professor of Interventional Radiology Vincent Vidal, M.D.
  • PhD, from the Aix-Marseille University and a Scientific Advisory Board Member of Microbot.
  • The team expressed their positive experiences and satisfaction from using the Company’s Robotic Surgery System.

IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress

Retrieved on: 
Friday, September 8, 2023
ENT, Endometriosis, CE, Abstract, IR, Plantar fibromatosis, Travel, Ablation, Cryoablation, Q&A, Neoplasm, Woman, Breast, CIRSE, Doctor of Philosophy, Lung, Congress, CHU, Traction, Freezing, Circulatory system, Cardiovascular and Interventional Radiological Society of Europe, Kidney, Liver, Malignancy, LN2, Medical imaging, Management, MD

IceCure will exhibit ProSense and provide hands-on demonstrations at booth #D56.

Key Points: 
  • IceCure will exhibit ProSense and provide hands-on demonstrations at booth #D56.
  • IceCure will be participating in the Tumor Ablation Hands-On Device Training with the ProSense cryoablation system.
  • This is a great opportunity for attendees to gain hands-on knowledge of IceCure's cryoablation device and to see the system's advantages.
  • Thanks to this grant, ten aspiring women interventional radiologists' abstracts were accepted and will receive sponsored congress registration, travel, and accommodation.

Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board

Retrieved on: 
Tuesday, July 11, 2023
SAB, EASL, Radiation, Society, European Society of Radiology, ZEUS robotic surgical system, ESR, Diagnosis, Editorial board, Woman, Abdominal Radiology, CIRSE, ILCA, Gastrointestinal tract, Interventional radiology, MD, Circulatory system, Executive Committee, Cardiovascular and Interventional Radiological Society of Europe, Health, Medical imaging, Radiology, Liver

Dr. Bargellini is the latest expansion of Microbot’s global presence with highly esteemed medical experts in large addressable markets.

Key Points: 
  • Dr. Bargellini is the latest expansion of Microbot’s global presence with highly esteemed medical experts in large addressable markets.
  • Dr. Bargellini’s primary clinical and scientific focus is on oncologic imaging and interventional oncology, with reference to liver imaging and liver tumors’ loco-regional and systemic therapies.
  • “It is encouraging that leading interventional radiologists continue to join Microbot as it embarks on the steps towards the commercialization of the system,” commented Eyal Morag, MD, Chief Medical Officer.
  • She serves as reviewer of several national and international journals and is Member of the Editorial Board of European Radiology and Cardiovascular and Interventional Radiology journals.

Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe

Retrieved on: 
Friday, June 16, 2023
Abstract, KOL, Cardiovascular and Interventional Radiological Society of Europe, Validation, Investigation, Disposable product, ICR, ZEUS robotic surgical system, Internet, Clinical trial, Compact, CIRSE, Circulatory system, V&V, FIH, IDE, FDA, Conference, Investigational device exemption, Safety, Medical device, Robotics

Further displaying their positive experiences and satisfaction, the Company has been informed that two peer-reviewed abstracts have been accepted to be presented at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Key Points: 
  • Further displaying their positive experiences and satisfaction, the Company has been informed that two peer-reviewed abstracts have been accepted to be presented at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
  • In addition, one of the abstracts was accepted as an oral presentation.
  • These peer-reviewed abstracts follow the highly successful extended joint pre-clinical animal studies held at leading European-based research labs by a team of seven renowned European interventional radiologists.
  • We believe that the current and future peer-reviewed data will accelerate adoption of LIBERTY once commercialized," said Dr. Eyal Morag, Chief Medical Officer of Microbot Medical.

Gerry O’Sullivan, the Latest Member to Join Microbot Medical’s Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY® Robotic System Through Regulatory, Clinical and Commercialization Phases

Retrieved on: 
Thursday, March 23, 2023
Well, Galway Clinic, SAB, IVC, KOL, Galway, Cardiovascular and Interventional Radiological Society of Europe, Society, Center of excellence, Intervention, Vision-guided robot systems, Consultant, Society of Interventional Radiology, Radiology, DVT, CIRSE, Prostate, Vein, SIR, Professor, Interventional radiology, Publication, Executive Committee, Clinical, SPC, European Board of Ophthalmology, Medical imaging

HINGHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to receive global interest from interventional radiologists due to the gap in new innovative technology currently available on the market today. Microbot Medical, the company developing the LIBERTY® Robotic System, the first single-use endovascular robotic system, today announced that Professor Gerry O’Sullivan, a key opinion leader (KOL) from Ireland, has joined the Company’s Scientific Advisory Board (SAB). The Company believes the combination of his academic and medical experience will be invaluable while it seeks to establish Centers of Excellence throughout the U.S. and Europe in preparation for human clinical trials.

Key Points: 
  • Microbot Medical, the company developing the LIBERTY® Robotic System, the first single-use endovascular robotic system, today announced that Professor Gerry O’Sullivan, a key opinion leader (KOL) from Ireland, has joined the Company’s Scientific Advisory Board (SAB).
  • Annually, Professor O’Sullivan performs large volumes of prostate and uterine fibroid embolizations, as well as the full array of Interventional procedures.
  • “I believe interventional radiologists have been seeking a better solution to address their concerns, while still achieving favorable patient outcomes.
  • For a complete list and background on the members of the SAB, please visit the Company’s website at www.microbotmedical.com .

Microbot Medical Increases Presence in the EU with the Addition of Greece-based Key Opinion Leader Stavros Spiliopoulos, MD, PhD, EBIR-ES, FCIRSE, to its Scientific Advisory Board

Retrieved on: 
Monday, March 13, 2023
Associate, Research, International Congress of Radiology, Doctor of Philosophy, Fair Employment Practice Committee, SAB, Dialysis, Radiology, KOL, Moyamoya disease, Committee, MD, IEEE SA International Award, American College, EU, Hospital, Titles of distinction awarded by the University of Oxford, Editorial board, Journal, European Board of Ophthalmology, Growth, Collection, Editor-in-chief, Interventional oncology, PubMed, Interventional radiology, Journal of Intelligent and Robotic Systems, Circulatory system, CIRSE, Medical imaging, Nursing

“I was quite impressed when I first used the LIBERTY® Robotic System, and I immediately recognized the significant clinical impact and needed to get involved,” commented Dr. Spiliopoulos.

Key Points: 
  • “I was quite impressed when I first used the LIBERTY® Robotic System, and I immediately recognized the significant clinical impact and needed to get involved,” commented Dr. Spiliopoulos.
  • “The addition of Dr. Spiliopoulos, the first member from Greece, reaffirms our commitment to recruit sought-after and well-published interventional radiologists across Europe and the Americas.
  • Dr. Spiliopoulos has published more than 200 peer-reviewed PubMed articles (more than 3.500 citations in Scopus) and 19 book chapters.
  • For a complete list and background on the members of the SAB, please visit www.microbotmedical.com .

Microbot Medical Expands its Geographic Presence to South America with the Addition of Francisco C. Carnevale, MD, PhD, FSIR to its Scientific Advisory Board

Retrieved on: 
Monday, February 27, 2023
Society, Vision-guided robot systems, Interventional radiology, Doctor of Philosophy, Urology, MD, RSNA, University, PAE, GEST, SAB, Harvard University, KOL, WCIO, Prostatic artery embolization, Cardiovascular and Interventional Radiological Society of Europe, Society of Interventional Radiology, Research, SIR, BPH, Patient, ISET, WAIS, CIRSE, Carnevale, Book, Hospital, ESR, Physician, Medical imaging, EU

HINGHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), today announced that it has expanded its global presence to South America with the addition of Francisco C. Carnevale, MD, PhD, FSIR, becoming the latest key opinion leader (KOL) to join the Company’s Scientific Advisory Board (SAB).

Key Points: 
  • HINGHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), today announced that it has expanded its global presence to South America with the addition of Francisco C. Carnevale, MD, PhD, FSIR, becoming the latest key opinion leader (KOL) to join the Company’s Scientific Advisory Board (SAB).
  • Dr. Carnevale, a vascular and interventional radiologist based in Sao Paolo, Brazil, is the Chief of the Vascular Interventional Radiology Section at Hospital das Clinicas - University of Sao Paulo Medical School Hospital (HC-FMUSP).
  • “Dr.
  • For a complete list and background on the members of Microbot’s SAB, please use this link

Microbot Medical Adds the Head of the Interventional Radiology Unit of Europe’s Largest Cancer Center, Dr. Thierry Jacques De Baère to its Scientific Advisory Board

Retrieved on: 
Monday, October 31, 2022
CVIR, U.S. Securities and Exchange Commission, SAB, ESMO, Intellectual property, Cardiovascular and Interventional Radiological Society of Europe, Physician, Robotics, Radiation exposure, MD, Adoption, Research, Journal, Private Securities Litigation Reform Act, Failure, CEO, Circulatory system, Forward-looking statement, Maintenance, Interventional radiology, Patient, SEC, Federal, Cancer, European Society of Radiology, Vision Guided Robotic Systems, Goal, 1, Company, Security (finance), CIRSE, Coronavirus Scientific Advisory Board (Turkey), GLOBE, Oncology, Doctor of Philosophy, Growth, NASDAQ, FDA, Technology, Time-invariant system, COVID-19, KOL, Nasdaq, European Society for Medical Oncology, Medicine, Medical device, Microbotics

HINGHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which is continuing to expand its Key Opinion Leader (KOL) support network, today announced that Thierry Jacques De Baère, MD, PhD, is joining the Company’s Scientific Advisory Board (SAB). Dr. De Baère is head of the Interventional Radiology Unit at Institut Gustave Roussy Cancer Center in Villejuif, France, the largest cancer center in Europe. The Company’s SAB now includes 11 members from the U.S., Europe and Israel, who support the rising momentum for the Company’s LIBERTY® Robotic System.

Key Points: 
  • Dr. De Bare is head of the Interventional Radiology Unit at Institut Gustave Roussy Cancer Center in Villejuif, France, the largest cancer center in Europe.
  • The Companys SAB now includes 11 members from the U.S., Europe and Israel, who support the rising momentum for the Companys LIBERTY Robotic System.
  • Dr. De Bare is a leader in the endovascular space, who realized the potential of the LIBERTY Robotic System after his own personal experience.
  • Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Microbot Medical Announce Strategic Addition to Scientific Advisory Board Appointment

Retrieved on: 
Tuesday, October 4, 2022
Maintenance, CIRSE, ARRT, Cancer, Oncology, RSNA, NASDAQ, Interventional radiology, Coronavirus Scientific Advisory Board (Turkey), Physician, SEC, Robotics, ACR, Gastrointestinal disease, Technology, Nasdaq, Research, Private Securities Litigation Reform Act, CEO, SUNY, MD, SIR, Interventional oncology, MD Anderson Cancer Center, ARRS, Internal medicine, Sudarshan K. Aggarwal, Federal, SIO, COVID-19, Failure, Goal, Growth, Vision Guided Robotic Systems, SCS, Section, AUR, U.S. Securities and Exchange Commission, Bernie Madoff, Safety, Journal, Yale school, Security (finance), Patient, Yale School of Medicine, University, Forward-looking statement, Portal vein, Publication, Intellectual property, Pittsburgh, GLOBE, SAB, Medical imaging, Pharmaceutical industry, Radiology, Medicine, Microbotics

HINGHAM, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which continues to be committed to expanding its capabilities, today announced the newest appointment to its Scientific Advisory Board (SAB), David C. Madoff, M.D.

Key Points: 
  • HINGHAM, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which continues to be committed to expanding its capabilities, today announced the newest appointment to its Scientific Advisory Board (SAB), David C. Madoff, M.D.
  • Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body.
  • Additional information on risks facing Microbot Medical can be found under the heading Risk Factors in Microbot Medicals periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SECs web site at www.sec.gov.
  • Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.